Literature DB >> 23528144

CYP2A6 genotype and smoking behavior in current smokers screened for lung cancer.

Mindi A Styn1, Tomoko Nukui, Marjorie Romkes, Kenneth A Perkins, Stephanie R Land, Joel L Weissfeld.   

Abstract

Functional CYP2A6 genetic variation partially determines nicotine metabolism. In 2005, we examined functional CYP2A6 variants associated with reduced metabolism (CYP2A6*2, CYP2A6*9, CYP2A6*4), smoking history, and change in smoking in 878 adult smokers undergoing lung cancer screening in an urban setting. At one year, 216 quit smoking for more than 30 days while 662 continued smoking. Compared to subjects who smoked 30 cigarettes per day at baseline, the odds of a reduced metabolism genotype was 52% higher in subjects smoking 20-29 cigarettes per day and 86% higher in subjects smoking less than 20 cigarettes per day (p-trend = 0.016). Reduced metabolism genotypes appeared unrelated to quitting. Though related to smoking dose, CYP2A6 may not influence cessation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23528144      PMCID: PMC3788637          DOI: 10.3109/10826084.2013.778280

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  11 in total

1.  CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR.

Authors:  Elke Schaeffeler; Matthias Schwab; Michel Eichelbaum; Ulrich M Zanger
Journal:  Hum Mutat       Date:  2003-12       Impact factor: 4.878

2.  Quitting smoking among adults--United States, 2001-2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-11-11       Impact factor: 17.586

3.  CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.

Authors:  Neal L Benowitz; Gary E Swan; Peyton Jacob; Christina N Lessov-Schlaggar; Rachel F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2006-11       Impact factor: 6.875

4.  Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy.

Authors:  C Lerman; C Jepson; E P Wileyto; F Patterson; R Schnoll; M Mroziewicz; N Benowitz; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2010-03-24       Impact factor: 6.875

5.  Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk.

Authors:  Catherine A Wassenaar; Qiong Dong; Qingyi Wei; Christopher I Amos; Margaret R Spitz; Rachel F Tyndale
Journal:  J Natl Cancer Inst       Date:  2011-07-11       Impact factor: 13.506

6.  Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot-Marie-Tooth type 1A disease and the peripheral myelin protein 22 deletion in hereditary neuropathy with liability to pressure palsies.

Authors:  N K Aarskog; C A Vedeler
Journal:  Hum Genet       Date:  2000-11       Impact factor: 4.132

7.  Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level.

Authors:  Andrew A Strasser; Neal L Benowitz; Angela G Pinto; Kathy Z Tang; Stephen S Hecht; Steve G Carmella; Rachel F Tyndale; Caryn E Lerman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-01-06       Impact factor: 4.254

8.  The impact of genetic variation in DRD2 and SLC6A3 on smoking cessation in a cohort of participants 1 year after enrollment in a lung cancer screening study.

Authors:  Mindi A Styn; Tomoko Nukui; Marjorie Romkes; Kenneth Perkins; Stephanie R Land; Joel L Weissfeld
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-03-05       Impact factor: 3.568

9.  Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine.

Authors:  Gary E Swan; Christina N Lessov-Schlaggar; Andrew W Bergen; Yungang He; Rachel F Tyndale; Neal L Benowitz
Journal:  Pharmacogenet Genomics       Date:  2009-05       Impact factor: 2.089

10.  Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data.

Authors:  Lisa Sanderson Cox; Babalola Faseru; Matthew S Mayo; Ron Krebill; Tricia S Snow; Carrie A Bronars; Nicole L Nollen; Won S Choi; Kolawole S Okuyemi; Gary A Salzman; Neal L Benowitz; Rachel F Tyndale; Jasjit S Ahluwalia
Journal:  Trials       Date:  2011-01-25       Impact factor: 2.279

View more
  7 in total

1.  Nicotine Metabolism in Young Adult Daily Menthol and Nonmenthol Smokers.

Authors:  Pebbles Fagan; Pallav Pokhrel; Thaddeus A Herzog; Ian S Pagano; Adrian A Franke; Mark S Clanton; Linda A Alexander; Dennis R Trinidad; Kari-Lyn K Sakuma; Carl A Johnson; Eric T Moolchan
Journal:  Nicotine Tob Res       Date:  2015-05-19       Impact factor: 4.244

2.  CYP2A6 Genetic Variation Alters Striatal-Cingulate Circuits, Network Hubs, and Executive Processing in Smokers.

Authors:  Sufang Li; Yihong Yang; Ewa Hoffmann; Rachel F Tyndale; Elliot A Stein
Journal:  Biol Psychiatry       Date:  2016-09-28       Impact factor: 13.382

Review 3.  Functional Neurocircuits and Neuroimaging Biomarkers of Tobacco Use Disorder.

Authors:  Matthew T Sutherland; Elliot A Stein
Journal:  Trends Mol Med       Date:  2018-02       Impact factor: 11.951

4.  Nicotine Metabolite Ratio (NMR) Prospectively Predicts Smoking Relapse: Longitudinal Findings From ITC Surveys in Five Countries.

Authors:  Brian V Fix; Richard J O'Connor; Neal Benowitz; Bryan W Heckman; K Michael Cummings; Geoffrey T Fong; James F Thrasher
Journal:  Nicotine Tob Res       Date:  2017-09-01       Impact factor: 4.244

5.  Nicotine Metabolism Predicted by CYP2A6 Genotypes in Relation to Smoking Cessation: A Systematic Review.

Authors:  Stephanie K Jones; Bethany J Wolf; Brett Froeliger; Kristin Wallace; Matthew J Carpenter; Anthony J Alberg
Journal:  Nicotine Tob Res       Date:  2022-03-26       Impact factor: 5.825

6.  Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population.

Authors:  Nada Ezzeldin; Dalia El-Lebedy; Amira Darwish; Ahmed El Bastawisy; Shereen Hamdy Abd Elaziz; Mirhane Mohamed Hassan; Amal Saad-Hussein
Journal:  BMC Cancer       Date:  2018-05-03       Impact factor: 4.430

7.  Genetic Factors Associated with COPD Depend on the Ancestral Caucasian/Amerindian Component in the Mexican Population.

Authors:  Gloria Pérez-Rubio; Ramcés Falfán-Valencia; Juan Carlos Fernández-López; Alejandra Ramírez-Venegas; Rafael de Jesús Hernández-Zenteno; Fernando Flores-Trujillo; Irma Silva-Zolezzi
Journal:  Diagnostics (Basel)       Date:  2021-03-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.